Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.

[1]  Akbar Ali,et al.  Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. , 2007, Journal of medicinal chemistry.

[2]  Younong Yu,et al.  A new synthesis of 3,4-disubstituted 1,2,5-thiadiazoles , 2007 .

[3]  Wei-Chang Fu,et al.  3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[4]  M. Dwyer,et al.  C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[5]  K. Ward,et al.  Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. , 2007, Bioorganic & medicinal chemistry letters.

[6]  M. Dwyer,et al.  Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. , 2006, Journal of medicinal chemistry.

[7]  J. D. Elliott,et al.  N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors. , 2006, Bioorganic & medicinal chemistry letters.

[8]  M. Dwyer,et al.  Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[9]  J. Busch-Petersen.  Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. , 2006, Current topics in medicinal chemistry.

[10]  John Unitt,et al.  Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[11]  H. Sajiki,et al.  Reductive and catalytic monoalkylation of primary amines using nitriles as an alkylating reagent. , 2004, Organic letters.

[12]  E. Lescop,et al.  Novel azapeptide inhibitors of hepatitis C virus serine protease. , 2004, Journal of medicinal chemistry.

[13]  J. D. Elliott,et al.  Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. , 2004, Journal of medicinal chemistry.

[14]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[15]  N. Iranpoor,et al.  Selective N-nitrosation of amines, N-alkylamides and N-alkylureas by N2O4 supported on cross-linked polyvinylpyrrolidone (PVP-N2O4) , 2003 .

[16]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[17]  D. Norbeck,et al.  Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. , 1999, Archives of biochemistry and biophysics.

[18]  J. Mestan,et al.  New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. , 1998, Journal of medicinal chemistry.

[19]  D. C. Iffland,et al.  Oxidation of N,N-Disubstituted Ketohydrazones by Lead Tetraacetate. Carbon—Nitrogen Bond Cleavage1 , 1963 .